The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD 16 (fc³RIII-A), or other Fcy or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signalling protein, such as FecRI-³, TCR-¾, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.
